
    
      -  Patients with non-ST elevation ACS will be randomized into pitavastatin 1mg or 4mg after
           everolimus-eluting stent implantation with OCT and NIRS study.

        -  12 months follow-up coronary angiography with OCT and NIRS will be performed to compare
           neointimal hyperplasia and atherosclerosis progression.

        -  36 months clinical follow-up for major adverse cardiovascular events (cardiac death,
           all-cause death, myocardial infarction, stroke, target lesion revascularization) will be
           compared.

        -  Safety issues such as bleeding rates, abnormal liver function will be compared
    
  